AION THERAPEUTIC INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.02 CAD | +33.33% |
|
-.--% | -.--% |
Valuation
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 6.072 | 1.467 | 11.23 | 2.836 | 1.473 |
| Enterprise Value (EV) 1 | 5.631 | 1.813 | 11.56 | 3.58 | 2.443 |
| P/E ratio | -1.09 x | -2.13 x | -1.02 x | -0.73 x | -5.7 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | -2,129,342 x | -4,672,059 x | -1,539,427 x | -2,900,222 x |
| EV / FCF | -2,596,429 x | -2,912,167 x | -5,166,716 x | -16,390,951 x | -4,815,101 x |
| FCF Yield | -0% | -0% | -0% | -0% | -0% |
| Price to Book | 2.56 x | 0.69 x | 28.3 x | -1.18 x | -0.54 x |
| Nbr of stocks (in thousands) | 31,139 | 36,682 | 124,805 | 141,799 | 147,299 |
| Reference price 2 | 0.1950 | 0.0400 | 0.0900 | 0.0200 | 0.0100 |
| Announcement Date | 8/28/19 | 7/10/20 | 10/29/21 | 11/1/22 | 8/28/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: April | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | -0.8516 | -2.474 | -2.326 | -0.8423 |
| EBIT 1 | -2.526 | -1.493 | -0.9627 | -2.602 | -2.391 | -0.8596 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.841 | -4.934 | -0.6728 | -8.265 | -3.818 | -0.2567 |
| Net income 1 | -2.841 | -4.934 | -0.6728 | -8.265 | -3.818 | -0.2567 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.3230 | -0.1796 | -0.0187 | -0.0880 | -0.0273 | -0.001753 |
| Free Cash Flow | - | -2.169 | -0.6227 | -2.237 | -0.2184 | -0.5074 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/12/18 | 8/28/19 | 7/10/20 | 10/29/21 | 11/1/22 | 8/28/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.35 | 0.33 | 0.74 | 0.97 |
| Net Cash position 1 | 3.79 | 0.44 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.4064 x | -0.132 x | -0.3199 x | -1.152 x |
| Free Cash Flow | - | -2.17 | -0.62 | -2.24 | -0.22 | -0.51 |
| ROE (net income / shareholders' equity) | - | -145% | -28.2% | -653% | 380% | 10% |
| ROA (Net income/ Total Assets) | - | -19% | -16.2% | -65.9% | -170% | -298% |
| Assets 1 | - | 25.97 | 4.162 | 12.55 | 2.241 | 0.0862 |
| Book Value Per Share 2 | 0.1800 | 0.0800 | 0.0600 | 0 | -0.0200 | -0.0200 |
| Cash Flow per Share 2 | 0.2200 | 0.0500 | 0.0200 | 0 | - | 0 |
| Capex | - | 1.95 | 0.2 | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 9/12/18 | 8/28/19 | 7/10/20 | 10/29/21 | 11/1/22 | 8/28/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 4.52M | |
| +39.33% | 6.01B | |
| -18.38% | 4.4B | |
| -9.17% | 3.17B | |
| +3.98% | 3.07B | |
| -3.41% | 2.51B | |
| +48.74% | 1.88B | |
| -4.82% | 1.73B | |
| -1.24% | 1.65B | |
| -8.96% | 1.58B |
- Stock Market
- Equities
- AION Stock
- Financials Aion Therapeutic Inc.
